Assessment of sleep in patients with lung cancer and breast cancer.

1993 ◽  
Vol 11 (5) ◽  
pp. 997-1004 ◽  
Author(s):  
P M Silberfarb ◽  
P J Hauri ◽  
T E Oxman ◽  
P Schnurr
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Adaptive Mechanism ◽  
Breast Cancer Patients ◽  
Sleep Difficulty ◽  
Lung Cancer Patients ◽  
Research Findings ◽  
Sleep Difficulties ◽  
Age And Sex

PURPOSE AND METHODS We studied the sleep architecture and psychologic state of 32 patients with breast or lung cancer compared with 32 age- and sex-matched, normal-sleeping volunteers and 32 otherwise healthy insomniacs. RESULTS Research findings indicate that lung cancer patients slept as poorly as did insomniacs, but underreported their sleep difficulties. Breast cancer patients slept similarly to normal-sleeping volunteers. No psychiatric disorders were detected in the cancer patients, and there were no significant differences in mood between lung and breast cancer patients. CONCLUSION Lung cancer patients appear to be unique in underestimating an objectively verified sleep difficulty. The adaptive mechanism of denial in these patients is discussed.

Outcome of patients with an initial presentation of brain metastases.

2014 ◽  
Vol 32 (31_suppl) ◽  
pp. 133-133
Author(s):  
Lawrence Berk ◽  
Bryan Stevens
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Radiation Therapy ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Median Survival ◽  
Survival Data ◽  
Breast Cancer Patients ◽  
Lung Cancer Patients ◽  
The Social

133 Background: Many studies have looked at the survival of patients with brain metastases but few studies have determined if the survival of patients initally presenting with brain metastases is the same as patients who subsequently develop brain metastases. Methods: Patients with no known history or a malignancy who presented to the hospital with brain metastases were retrospectively revieweed for survival. The survival data were collected from the hospital's tumor registryand the Social Security Index. The years 2010-2011 were studied as of 5/31/2013. Results: Ninety-four patients met the inclusion criteria in 2010 and eight-two patients in 2011. Sixty five percent of the patients in 2010 were male and fifty-five percent were male in 2011. The median age was approximately 60. In 2010 53% of the patients had lung cancer and 12% had breast cancer and in 2011 45% had lung cancer and 13% had breast cancer. zThus the median survival is equivalent to the median survival of the lung cancer patients, which was 71 days in 2010 and 37 days in 2011. the median survival of the breast cancer patients were 153 days in 2010 and 35 days in 2011. Sixty three percent of the patients received radiation therapy as some part of their treatment and eighteen percent received no treatment. The median survival time of patients receiving radiation therapy only as treatment was 84 days and the patients with no treatment had a survival of 34 days. Conclusions: The survival of patients presenting with brain metastases falls within the range expected from previous studies of patients with brain metastases. The survival of patients presenting with lung cancer was much poorer than patients with breast cancer. Patients for no treatment appear to be appropriately selected, with a median surival of approximately one month.

Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4856-4856
Author(s):  
Andreas Lammerich ◽  
Igor Bondarenko ◽  
Udo Müller
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Cardiac Repolarization ◽  
Interval Duration ◽  
Breast Cancer Patients ◽  
Lung Cancer Patients ◽  
Cancer Study ◽  
Breast Cancer Study ◽  
Tendency Analysis

Abstract Background Chemotherapy (CTx) may cause adverse events such as neutropenia, febrile neutropenia (FN), and cardiotoxicity. Lipegfilgrastim is a once-per-cycle, fixed-dose, glycoPEGylated granulocyte colony-stimulating factor (G-CSF) being developed to reduce the duration of neutropenia and the incidence of FN in cancer patients receiving CTx. Pegfilgrastim is a long-acting covalent conjugate of recombinant methionyl human G-CSF and monomethoxypolyethylene glycol currently available to decrease infection, as manifested by FN, in cancer patients receiving myelosuppressive anti-cancer drugs. Cardiovascular events have seldom been reported in patients receiving colony-stimulating factors. Objective To evaluate any possible contributions to the electrocardiogram (ECG) effects of CTx after administration of lipegfilgrastim in lung cancer (vs placebo) and breast cancer (vs pegfilgrastim) patients. Methods This analysis is based on 2 phase III studies. Lung cancer patients were given lipegfilgrastim 6 mg (n=248) or placebo (n=125) subcutaneously (SC) once per cycle ∼24 h after CTx (cisplatin, 80 mg/m2/etoposide, 120 mg/m2) for a maximum of 4 cycles. Breast cancer patients were given lipegfilgrastim 6 mg (n=101) or pegfilgrastim 6 mg (n=101) SC once per cycle ∼24 h after CTx (doxorubicin, 60 mg/m2/docetaxel, 75 mg/m2) for a maximum of 4 cycles. ECG analysis was performed on all enrolled patients with ≥1 baseline and 1 on-treatment ECG. Monitoring was performed at baseline (∼24 h before CTx, cycle 1), 24 h after study drug administration in cycles 1 and 4, and at the end-of-study visit. ECG measurements included RR, PR, QRS, and QT intervals; derived variables included QTcF (Fridericia’s formula), QTcB (Bazett’s formula), and heart rate (HR). Central tendency analysis compared baseline ECG values with those during cycle 1, 4, and at end of study. Outlier analysis determined if there were any patients with exaggerated effects on ECG intervals not revealed by central tendency analysis. Morphologic analyses were performed with regard to ECG waveform. Results Changes from baseline placebo-corrected values (lung cancer patients) or baseline (breast cancer patients) for HR, PR and QRS interval duration were not clinically relevant, with no difference between lipegfilgrastim and pegfilgrastim in breast cancer patients. Mean changes from baseline placebo-corrected QTcF interval duration showed no signal effect for lipegfilgrastim on cardiac repolarization in lung cancer patients. Changes in QTcF interval duration between lipegfilgrastim and pegfilgrastim in breast cancer patients were comparable. There were no bradycardic outliers in lung cancer patients treated with lipegfilgrastim and 1 at the end of study in breast cancer patients. In the lung cancer study, there were 4%, 2%, and 4% tachycardic outliers in cycle 1, 4, and end of study, respectively, for patients treated with lipegfilgrastim versus 4%, 0%, and 2% in patients receiving placebo. In the breast cancer study, there were 0%, 4%, and 2% tachycardic outliers in cycle 1, 4, and end of study, respectively, for patients treated with lipegfilgrastim versus 1%, 2%, and 1% in patients treated with pegfilgrastim. There were no outliers for PR interval duration in either study. In the lung cancer study, there were 2%, 1%, and 2% QRS outliers in cycle 1, 4, and end of study, respectively, for lipegfilgrastim-treated patients versus 1%, 0%, and 0% in patients receiving placebo. There was only 1 QRS outlier in the breast cancer study (lipegfilgrastim-treated patient, cycle 1). New morphologic changes from baseline were in ST segment and negative T wave inversions and considered nonspecific. Conclusions There was no clear effect of lipegfilgrastim on HR, AV nodal conduction measured by PR interval duration, cardiac depolarization measured by QRS duration, or morphology, and no clear signal of effect on cardiac repolarization in the lung cancer study. In the breast cancer study, treatment with lipegfilgrastim and pegfilgrastim had no effect on ECG parameters except for nonspecific ST-T changes and a comparable increase in QTcF (cardiac repolarization) in the 10-15 ms range. The lack of ECG effect versus placebo in the lung cancer study along with the presence of potential QTcF changes in the breast cancer study suggest that the changes observed in the breast cancer study may be due to causes other than the G-CSF treatment. Disclosures: Lammerich: Merckle/ratiopharm/Teva Pharm Industries: Employment. Müller:Teva Pharmaceuticals, Inc: Employment.

scholarly journals A meta-analysis of Watson for Oncology in clinical application

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Zhou Jie ◽  
Zeng Zhiying ◽  
Li Li
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Small Cell ◽  
Breast Cancer Patients ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Colorectal Cancer Patients

AbstractUsing the method of meta-analysis to systematically evaluate the consistency of treatment schemes between Watson for Oncology (WFO) and Multidisciplinary Team (MDT), and to provide references for the practical application of artificial intelligence clinical decision-support system in cancer treatment. We systematically searched articles about the clinical applications of Watson for Oncology in the databases and conducted meta-analysis using RevMan 5.3 software. A total of 9 studies were identified, including 2463 patients. When the MDT is consistent with WFO at the ‘Recommended’ or the ‘For consideration’ level, the overall concordance rate is 81.52%. Among them, breast cancer was the highest and gastric cancer was the lowest. The concordance rate in stage I–III cancer is higher than that in stage IV, but the result of lung cancer is opposite (P < 0.05).Similar results were obtained when MDT was only consistent with WFO at the "recommended" level. Moreover, the consistency of estrogen and progesterone receptor negative breast cancer patients, colorectal cancer patients under 70 years old or ECOG 0, and small cell lung cancer patients is higher than that of estrogen and progesterone positive breast cancer patients, colorectal cancer patients over 70 years old or ECOG 1–2, and non-small cell lung cancer patients, with statistical significance (P < 0.05). Treatment recommendations made by WFO and MDT were highly concordant for cancer cases examined, but this system still needs further improvement. Owing to relatively small sample size of the included studies, more well-designed, and large sample size studies are still needed.

Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study

2017 ◽  
Vol 48 ◽  
pp. 22-28 ◽  
Author(s):  
Sung-Chao Chu ◽  
Chia-Jung Hsieh ◽  
Tso-Fu Wang ◽  
Mun-Kun Hong ◽  
Tang-Yuan Chu
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Population Based Study

scholarly journals P09.27 Descriptive Review of Breast Cancer Patients With Subsequent Lung Cancer

2021 ◽  
Vol 16 (3) ◽  
pp. S302
Author(s):  
M. Noor ◽  
C. Lee ◽  
E. Miao ◽  
S. Cohen ◽  
H. Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients

scholarly journals Integrated sequence and gene expression analysis of mouse models of breast cancer reveals critical events with human parallels

2018 ◽  
Author(s):  
Jonathan P Rennhack ◽  
Matthew Swiatnicki ◽  
Yueqi Zhang ◽  
Caralynn Li ◽  
Evan Bylett ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Mouse Models ◽  
Copy Number ◽  
Human Breast Cancer ◽  
Human Cancer ◽  
Copy Number Alterations ◽  
Human Breast ◽  
Lung Cancer Patients

AbstractMouse models have an essential role in cancer research, yet little is known about how various models resemble human cancer at a genomic level. However, the shared genomic alterations in each model and corresponding human cancer are critical for translating findings in mice to the clinic. We have completed whole genome sequencing and transcriptome profiling of two widely used mouse models of breast cancer, MMTV-Neu and MMTV-PyMT. This genomic information was integrated with phenotypic data and CRISPR/Cas9 studies to understand the impact of key events on tumor biology. Despite the engineered initiating transgenic event in these mouse models, they contain similar copy number alterations, single nucleotide variants, and translocation events as human breast cancer. Through integrative in vitro and in vivo studies, we identified copy number alterations in key extracellular matrix proteins including Collagen 1 Type 1 alpha 1 (Col1a1) and Chondroadherin (CHAD) that drive metastasis in these mouse models. Importantly this amplification is also found in 25% of HER2+ human breast cancer and is associated with increased metastasis. In addition to copy number alterations, we observed a propensity of the tumors to modulate tyrosine kinase mediated signaling through mutation of phosphatases. Specifically, we found that 81% of MMTV-PyMT tumors have a mutation in the EGFR regulatory phosphatase, PTPRH. Mutation in PTPRH led to increased phospho-EGFR levels and decreased latency. Moreover, PTPRH mutations increased response to EGFR kinase inhibitors. Analogous PTPRH mutations are present in lung cancer patients and together this data suggests that a previously unidentified population of human lung cancer patients may respond to EGFR targeted therapy. These findings underscore the importance of understanding the complete genomic landscape of a mouse model and illustrate the utility this has in understanding human cancers.

scholarly journals Higher Mortality Rates in Breast and Lung Cancer Patients Admitted for Febrile Neutropenia: An Analysis of Outcomes Based on Data from the Nationwide Inpatient Sample from 2006-2013

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5904-5904
Author(s):  
Ankit Shah ◽  
Stuthi Perimbeti ◽  
Sumera Bukhari ◽  
Michael Wismer ◽  
Jordan Senchak ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Length Of Stay ◽  
Febrile Neutropenia ◽  
Hospital Mortality ◽  
Cancer Patients ◽  
Mortality Rates ◽  
Primary Diagnosis ◽  
Lung Cancer Patients ◽  
Total Charges

Abstract Background: Febrile neutropenia is associated with significant morbidity, mortality, healthcare resource utilization and associated cost. However, data regarding the relationship of specific cancers with admission for febrile neutropenia and their outcomes is lacking. Methods: Using the ICD-9 codes 288.00 and 288.04, we identified all adult admissions with primary diagnosis of febrile neutropenia during the interval of 2006-2013 from the Nationwide Inpatient Sample (NIS). Hospitalization information regarding mortality rates, length of stay and total charges was extracted for each year. Total cost was adjusted for inflation using data from the U.S. Bureau of Labor Statistics. Differences in these variables in teaching and nonteaching institutions were evaluated. ICD-9 codes for esophageal, colon, rectal, liver, pancreatic, bladder, prostate, cervical, renal, thyroid, lung, and melanoma skin cancers were selected and the percentage of admissions attributed to each malignancy was determined. Results: We identified 48,253 admissions (weighted N = 233,116) with a primary diagnosis of febrile neutropenia from 2006-2013. Most of these admissions occurred at teaching institutions (n=28,902, weighted n=139,574). In-hospital mortality rates for febrile neutropenia had a downward trend over the time period of 2006-2013 although the difference was not statistically significant (p=.082). Specifically, the in-hospital mortality rate was 2.73% in 2006 and 1.35% in 2013. Mean length of stay (days) has decreased from 5.67 (±.16) in 2006 to 5.32 (±0.06) in 2013 (p=.0001) while total charges have increased from $29,113 (±1089) in 2006 to $41,713 (±726) in 2013 (p=.0001). This is greater than the expected inflationary change from $29,133 to $33,641 over the same time period. Mean length of stay (days) was found to be higher at teaching (5.89±.03) than at non-teaching (5.25±.04) hospitals (p=.0001). Similarly, mean total charges were higher in teaching ($41,577±364) than in non-teaching ($34,176±345) institutions (p=.0001). When comparing teaching vs. non-teaching institutions, in-hospital mortality was not found to have a statistically significant difference (p=.2688). Of the 13 malignancies queried, lung cancer (11.06%) and breast cancer (8.40%) accounted for more admissions for febrile neutropenia than the other malignancies selected. Breast cancer (3.62%, p=.0001) and lung cancer (16.11%, p=.0001) were also associated with much higher in-hospital mortality rates compared with the other malignancies selected. Conclusions: Breast and lung cancer account for a significant number of admissions for febrile neutropenia, which is consistent with their national prevalence. Of particular note,breast and lung cancer patients who were admitted for febrile neutropenia had a higher risk of mortality. In lung cancer, the frequently associated smoking-related comorbidities may be contributing to this finding. While in breast cancer, patients with advanced disease have an increase in cumulative lifetime dose of chemotherapy due to prolonged survival and this may result in a weakened bone marrow, a more susceptible patient, and consequently an increase in febrile neutropenia and mortality rates. Thus, given the greater mortality rate and significant number of patients affected, patients with these two malignancies should receive special attention to ensure they receive prophylaxis with granulocyte stimulating agents and/or antibiotics after treatment with cytotoxic chemotherapy. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

scholarly journals Effects of Behavioral Activation on the Quality of Life and Emotional State of Lung Cancer and Breast Cancer Patients During Chemotherapy Treatment

2017 ◽  
Vol 43 (2) ◽  
pp. 151-180 ◽  
Author(s):  
Concepción Fernández-Rodríguez ◽  
Erica Villoria-Fernández ◽  
Paula Fernández-García ◽  
Sonia González-Fernández ◽  
Marino Pérez-Álvarez
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Behavioral Activation ◽  
Emotional State ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Chemotherapy Treatment

Research suggests that the progressive abandonment of activities in cancer patients are related to depression and worse quality of life. Behavioral activation (BA) encourages subjects to activate their sources of reinforcement and modify the avoidance responses. This study assesses the effectiveness of BA in improving quality of life and preventing emotional disorders during chemotherapy treatment. One sample of lung cancer patients and another of breast cancer patients were randomized into a BA experimental group (E.G.lung/4sess. n = 50; E.G.breast/6sess. n = 33) and a control group (C.G.lung/4sess. n = 40; C.G.breast/6sess. n = 35), respectively. In each session and in follow-ups (3/6/9 months), all participants completed different assessment scales. The results converge to show the effectiveness of BA, encouraging cancer patients to maintain rewarding activities which can activate their sources of day-to-day reinforcement and modify their experience avoidance patterns. BA appears to be a practical intervention which may improve social and role functioning and the emotional state of cancer patients during chemotherapy treatment.

Sign in / Sign up

Export Citation Format

Share Document